Media
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period
05-11-2020
Media AnnouncementsMelbourne, 5 November 2020 – PolyActiva Pty Ltd, a clinical-stage Australian ophthalmology biopharmaceutical company, today announced it has successfully completed its Phase I clinical study for its lead candidate, the Latanoprost FA SR Ocular Implant. The device was well tolerated in all 8 patients with no significant safety findings….
PolyActiva appoints Tracy Valorie, ophthalmic industry expert and former Bausch + Lomb executive, to its Board of Directors
30-10-2020
Media AnnouncementsMelbourne, Australia – 30 October 2020: PolyActiva Pty Ltd, a clinical-stage ophthalmology biopharmaceutical company, today announced the appointment of a highly experienced ophthalmic industry expert, Tracy Valorie, as a new member to the company’s Board of Directors. Ms Valorie is recognized in the industry for her success in…
Intra-articular Treatment of Osteoarthritis with Diclofenac-Conjugated Polymer Reduces Inflammation and Pain
27-11-2019
Media Publications- Authors:
- Adrian Sulistio, Friederike M. Mansfeld, Felisa Reyes-Ortega, Asha M. D’Souza, Sarah M. Y. Ng, Stephen Birkett, Anton Blencowe, Greg G. Qiao, Christopher B. Little, Cindy C. Shu, Alison M. Bendele, David Valade, Andrew C. Donohue, John F. Quinn, Michael R. Whittaker, Thomas P. Davis, and Russell J. Tait
ACS Appl. Bio Mater (2019), 2, 2822−2832. DOI: 10.1021/acsabm.9b00232. Published: 24 May 2019.
Our Unique Technology
30-10-2019
Media VideosAn update on PolyActiva’s drug delivery platform, showcasing its Latanoprost FA SR Ocular Implant for the treatment of glaucoma.
PolyActiva completes recruitment in key Phase I glaucoma implant safety study. Six-month treatment period demonstrated.
24-07-2019
Media AnnouncementsJuly 23, Chicago – PolyActiva Pty Ltd, a clinical-stage biotechnology company and leader in ocular drug delivery, has completed patient enrolment for its Phase I clinical trial to study safety and tolerability of its biodegradable, slow-release ocular implant for the treatment of glaucoma…